Actively Recruiting
A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2026-04-16
138
Participants Needed
1
Research Sites
155 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a multicenter, open-label, dose-escalation/dose-expansion clinical Phase I trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy profile of SHR-9539 Injection in patients with multiple myeloma.
CONDITIONS
Official Title
A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older at the time of informed consent
- Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale
- Confirmed diagnosis of multiple myeloma according to IMWG criteria
- Life expectancy of at least 3 months
- Agree to use effective contraception during the study and for 3 months after last drug dose, with negative pregnancy test at screening
You will not qualify if you...
- Central nervous system involvement of multiple myeloma
- Diagnosis of amyloidosis, plasma cell leukemia, Wahl's macroglobulinemia, or POEMS syndrome
- Prior Grade 3 or higher cytokine release syndrome related to any T cell redirection therapy
- Other serious illnesses, psychiatric conditions, or social/family factors that may affect safety or study compliance as determined by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
West China Hospital of Sichuan University
Chengdu, Sichuan, China, 610000
Actively Recruiting
Research Team
Y
Yang Wu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here